3.22.4 html 87 224 1 false 37 0 false 5 false false R1.htm 0000001 - Document - Cover Sheet http://www.vallon-pharma.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Statement - Balance Sheets Sheet http://www.vallon-pharma.com/role/BalanceSheets Balance Sheets Statements 2 false false R3.htm 0000003 - Statement - Balance Sheets (Parenthetical) Sheet http://www.vallon-pharma.com/role/BalanceSheetsParenthetical Balance Sheets (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - Statement of Operations and Comprehensive Loss Sheet http://www.vallon-pharma.com/role/StatementofOperationsandComprehensiveLoss Statement of Operations and Comprehensive Loss Statements 4 false false R5.htm 0000005 - Statement - Statements of Changes in Stockholders??? Equity (Deficit) Sheet http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit Statements of Changes in Stockholders??? Equity (Deficit) Statements 5 false false R6.htm 0000006 - Statement - Statements of Cash Flows Sheet http://www.vallon-pharma.com/role/StatementsofCashFlows Statements of Cash Flows Statements 6 false false R7.htm 0000007 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS Sheet http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS ORGANIZATION AND DESCRIPTION OF BUSINESS Notes 7 false false R8.htm 0000008 - Disclosure - LIQUIDITY Sheet http://www.vallon-pharma.com/role/LIQUIDITY LIQUIDITY Notes 8 false false R9.htm 0000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 0000010 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS Sheet http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTS MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS Notes 10 false false R11.htm 0000011 - Disclosure - LEASES Sheet http://www.vallon-pharma.com/role/LEASES LEASES Notes 11 false false R12.htm 0000012 - Disclosure - ACCRUED EXPENSES Sheet http://www.vallon-pharma.com/role/ACCRUEDEXPENSES ACCRUED EXPENSES Notes 12 false false R13.htm 0000013 - Disclosure - PPP NOTE AND CONVERTIBLE NOTES Notes http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTES PPP NOTE AND CONVERTIBLE NOTES Notes 13 false false R14.htm 0000014 - Disclosure - EMPLOYEE BENEFIT PLANS Sheet http://www.vallon-pharma.com/role/EMPLOYEEBENEFITPLANS EMPLOYEE BENEFIT PLANS Notes 14 false false R15.htm 0000015 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 15 false false R16.htm 0000016 - Disclosure - STOCKHOLDERS EQUITY (DEFICIT) Sheet http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICIT STOCKHOLDERS EQUITY (DEFICIT) Notes 16 false false R17.htm 0000017 - Disclosure - STOCK-BASED COMPENSATION Sheet http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION STOCK-BASED COMPENSATION Notes 17 false false R18.htm 0000018 - Disclosure - INCOME TAX Sheet http://www.vallon-pharma.com/role/INCOMETAX INCOME TAX Notes 18 false false R19.htm 0000019 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONS RELATED PARTY TRANSACTIONS Notes 19 false false R20.htm 0000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 20 false false R21.htm 0000021 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Tables) Sheet http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSTables MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Tables) Tables http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTS 21 false false R22.htm 0000022 - Disclosure - LEASES (Tables) Sheet http://www.vallon-pharma.com/role/LEASESTables LEASES (Tables) Tables http://www.vallon-pharma.com/role/LEASES 22 false false R23.htm 0000023 - Disclosure - ACCRUED EXPENSES (Tables) Sheet http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables ACCRUED EXPENSES (Tables) Tables http://www.vallon-pharma.com/role/ACCRUEDEXPENSES 23 false false R24.htm 0000024 - Disclosure - STOCKHOLDERS EQUITY (DEFICIT) (Tables) Sheet http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITTables STOCKHOLDERS EQUITY (DEFICIT) (Tables) Tables http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICIT 24 false false R25.htm 0000025 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables STOCK-BASED COMPENSATION (Tables) Tables http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION 25 false false R26.htm 0000026 - Disclosure - INCOME TAX (Tables) Sheet http://www.vallon-pharma.com/role/INCOMETAXTables INCOME TAX (Tables) Tables http://www.vallon-pharma.com/role/INCOMETAX 26 false false R27.htm 0000027 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details) Sheet http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails ORGANIZATION AND DESCRIPTION OF BUSINESS (Details) Details http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS 27 false false R28.htm 0000028 - Disclosure - LIQUIDITY (Details) Sheet http://www.vallon-pharma.com/role/LIQUIDITYDetails LIQUIDITY (Details) Details http://www.vallon-pharma.com/role/LIQUIDITY 28 false false R29.htm 0000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Recapitalization and License Revenue (Details) Sheet http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRecapitalizationandLicenseRevenueDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Recapitalization and License Revenue (Details) Details 29 false false R30.htm 0000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details) Sheet http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details) Details 30 false false R31.htm 0000031 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of the Company???s Available for Sale Securities (Details) Sheet http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of the Company???s Available for Sale Securities (Details) Details 31 false false R32.htm 0000032 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value (Details) Sheet http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueDetails MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value (Details) Details 32 false false R33.htm 0000033 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Narrative (Details) Sheet http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSNarrativeDetails MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Narrative (Details) Details http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSTables 33 false false R34.htm 0000034 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Liability Measured at Estimated Fair Value (Details) Sheet http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Liability Measured at Estimated Fair Value (Details) Details 34 false false R35.htm 0000035 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Derivative Liability Measurement Inputs (Details) Sheet http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Derivative Liability Measurement Inputs (Details) Details 35 false false R36.htm 0000036 - Disclosure - LEASES - Assets and Liabilities (Details) Sheet http://www.vallon-pharma.com/role/LEASESAssetsandLiabilitiesDetails LEASES - Assets and Liabilities (Details) Details 36 false false R37.htm 0000037 - Disclosure - ACCRUED EXPENSES (Details) Sheet http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails ACCRUED EXPENSES (Details) Details http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables 37 false false R38.htm 0000038 - Disclosure - PPP NOTE AND CONVERTIBLE NOTES (Details) Notes http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails PPP NOTE AND CONVERTIBLE NOTES (Details) Details http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTES 38 false false R39.htm 0000039 - Disclosure - EMPLOYEE BENEFIT PLANS (Details) Sheet http://www.vallon-pharma.com/role/EMPLOYEEBENEFITPLANSDetails EMPLOYEE BENEFIT PLANS (Details) Details http://www.vallon-pharma.com/role/EMPLOYEEBENEFITPLANS 39 false false R40.htm 0000040 - Disclosure - COMMITMENTS AND CONTINGENCIES - Litigation (Details) Sheet http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESLitigationDetails COMMITMENTS AND CONTINGENCIES - Litigation (Details) Details 40 false false R41.htm 0000041 - Disclosure - STOCKHOLDERS EQUITY (DEFICIT) - Narrative (Details) Sheet http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITNarrativeDetails STOCKHOLDERS EQUITY (DEFICIT) - Narrative (Details) Details http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITTables 41 false false R42.htm 0000042 - Disclosure - STOCKHOLDERS EQUITY (DEFICIT) - Estimate of the Fair Value of the Warrants and Assumptions (Details) Sheet http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails STOCKHOLDERS EQUITY (DEFICIT) - Estimate of the Fair Value of the Warrants and Assumptions (Details) Details http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITTables 42 false false R43.htm 0000043 - Disclosure - STOCKHOLDERS EQUITY (DEFICIT) - Schedule of Warrants Outstanding to Purchase Common Stock (Details) Sheet http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails STOCKHOLDERS EQUITY (DEFICIT) - Schedule of Warrants Outstanding to Purchase Common Stock (Details) Details http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITTables 43 false false R44.htm 0000044 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details) Sheet http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details) Details 44 false false R45.htm 0000045 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details) Sheet http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails STOCK-BASED COMPENSATION - Narrative (Details) Details 45 false false R46.htm 0000046 - Disclosure - STOCK-BASED COMPENSATION - Activity of Stock Options (Details) Sheet http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails STOCK-BASED COMPENSATION - Activity of Stock Options (Details) Details 46 false false R47.htm 0000047 - Disclosure - STOCK-BASED COMPENSATION - Assumptions Used to Estimate Fair Value of Options (Details) Sheet http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails STOCK-BASED COMPENSATION - Assumptions Used to Estimate Fair Value of Options (Details) Details 47 false false R48.htm 0000048 - Disclosure - STOCK-BASED COMPENSATION - Restricted Stock Unit Activity (Details) Sheet http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitActivityDetails STOCK-BASED COMPENSATION - Restricted Stock Unit Activity (Details) Details 48 false false R49.htm 0000049 - Disclosure - INCOME TAX - Reconciliation of Federal Statutory Income Tax Rate to the Effective Income Tax Rate (Details) Sheet http://www.vallon-pharma.com/role/INCOMETAXReconciliationofFederalStatutoryIncomeTaxRatetotheEffectiveIncomeTaxRateDetails INCOME TAX - Reconciliation of Federal Statutory Income Tax Rate to the Effective Income Tax Rate (Details) Details 49 false false R50.htm 0000050 - Disclosure - INCOME TAX- Components of Deferred Tax Assets (Details) Sheet http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxAssetsDetails INCOME TAX- Components of Deferred Tax Assets (Details) Details 50 false false R51.htm 0000051 - Disclosure - INCOME TAX - Narrative (Details) Sheet http://www.vallon-pharma.com/role/INCOMETAXNarrativeDetails INCOME TAX - Narrative (Details) Details 51 false false R52.htm 0000052 - Disclosure - RELATED PARTY TRANSACTIONS (Details) Sheet http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails RELATED PARTY TRANSACTIONS (Details) Details http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONS 52 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 - val-20230224.htm 4 val-20230224.htm exhibit1040-sx4a3.htm exhibit1041-sx4a3.htm exhibit1042-sx4a3.htm exhibit107-sx4a3.htm exhibit231-sx4a3.htm exhibit232-sx4a3.htm exhibit995-sx4a3.htm exhibit996-sx4a3.htm val-20230224.xsd val-20230224_cal.xml val-20230224_def.xml val-20230224_lab.xml val-20230224_pre.xml val-20230224_g1.jpg val-20230224_g10.jpg val-20230224_g11.jpg val-20230224_g12.jpg val-20230224_g13.jpg val-20230224_g14.jpg val-20230224_g15.jpg val-20230224_g16.jpg val-20230224_g17.jpg val-20230224_g18.jpg val-20230224_g2.jpg val-20230224_g3.jpg val-20230224_g4.jpg val-20230224_g5.jpg val-20230224_g6.jpg val-20230224_g7.jpg val-20230224_g8.jpg val-20230224_g9.jpg http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true